About Neuralstem (NASDAQ:CUR)
Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CUR
CUSIPN/A
Phone301-366-4841
Debt
Debt-to-Equity RatioN/A
Current Ratio8.24%
Quick Ratio8.24%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$260,000.00
Price / Sales96.79
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book2.96
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-15,660,000.00
Net Margins-8,075.26%
Return on Equity-137.90%
Return on Assets-83.33%
Miscellaneous
Employees6
Outstanding Shares15,160,000
Neuralstem (NASDAQ:CUR) Frequently Asked Questions
What is Neuralstem's stock symbol?
Neuralstem trades on the NASDAQ under the ticker symbol "CUR."
How were Neuralstem's earnings last quarter?
Neuralstem, Inc. (NASDAQ:CUR) released its quarterly earnings results on Monday, April, 2nd. The company reported ($0.20) EPS for the quarter. The business earned $0.19 million during the quarter. Neuralstem had a negative net margin of 8,075.26% and a negative return on equity of 137.90%. View Neuralstem's Earnings History.
What price target have analysts set for CUR?
0 brokers have issued twelve-month target prices for Neuralstem's shares. Their forecasts range from $1.91 to $1.91. On average, they expect Neuralstem's share price to reach $1.91 in the next year. View Analyst Ratings for Neuralstem.
Who are some of Neuralstem's key competitors?
Some companies that are related to Neuralstem include Krystal Biotech (KRYS), Applied Genetic Technologies (AGTC), Aevi Genomic Medicine (GNMX), Curis (CRIS), Cidara Therapeutics (CDTX), aTyr Pharma (LIFE), Genocea Biosciences (GNCA), Brainstorm Cell Therapeutics (BCLI), TRACON Pharmaceuticals (TCON), CytRx (CYTR), Champions Oncology (CSBR), BiondVax (BVXV), Proteon Therapeutics (PRTO), Vaxart (VXRT) and Microbot Medical (MBOT).
Who are Neuralstem's key executives?
Neuralstem's management team includes the folowing people:
- Mr. Richard J. Daly, Chairman, CEO, Pres and Interim Principal Financial & Accounting Officer (Age 57)
- Dr. Karl Y. Johe Ph.D., Co-Founder & Chief Scientific Officer (Age 58)
- Danielle Spangler, Director of Investor Relations
- Dr. Thomas G. Hazel Ph.D., Sr. VP of Research
- Dr. David P. Recker, Chief Medical Officer (Age 60)
Has Neuralstem been receiving favorable news coverage?
Headlines about CUR stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neuralstem earned a media sentiment score of 0.25 on Accern's scale. They also gave headlines about the company an impact score of 46.31 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Neuralstem?
Shares of CUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neuralstem's stock price today?
One share of CUR stock can currently be purchased for approximately $1.66.
How big of a company is Neuralstem?
Neuralstem has a market capitalization of $24.71 million and generates $260,000.00 in revenue each year. Neuralstem employs 6 workers across the globe.
How can I contact Neuralstem?
Neuralstem's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 301-366-4841 or via email at [email protected]
MarketBeat Community Rating for Neuralstem (CUR)
MarketBeat's community ratings are surveys of what our community members think about Neuralstem and other stocks. Vote "Outperform" if you believe CUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Neuralstem (NASDAQ:CUR) Earnings History and Estimates Chart
Neuralstem (NASDAQ CUR) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 4/2/2018 | Q4 2017 | | ($0.20) | | $0.19 million | View | N/A |  |
| 11/13/2017 | Q3 2017 | | ($0.18) | | | View | N/A | |
| 8/8/2017 | Q2 2017 | ($9.49) | ($0.39) | | | View | N/A | |
| 5/10/2017 | Q1 2017 | | ($0.43) | | | View | N/A | |
| 11/8/2016 | Q3 | ($0.03) | ($0.05) | | | View | N/A | |
| 8/11/2016 | Q2 | ($0.05) | ($0.04) | $2.50 million | $2.50 million | View | N/A | |
| 5/9/2016 | Q1 | ($0.06) | ($0.07) | | | View | N/A | |
| 3/14/2016 | Q4 | ($0.07) | ($0.05) | | | View | N/A | |
| 11/9/2015 | Q315 | ($0.07) | ($0.06) | | | View | N/A | |
| 8/10/2015 | Q2 | ($0.06) | ($0.06) | | | View | N/A | |
| 5/8/2015 | Q115 | ($0.07) | ($0.06) | | $2.92 million | View | N/A | |
| 4/20/2015 | | ($0.07) | ($0.06) | | | View | N/A | |
| 3/16/2015 | Q4 2014 | ($0.05) | ($0.06) | | $0.01 million | View | N/A | |
| 11/7/2014 | Q314 | ($0.05) | ($0.05) | | $0.01 million | View | N/A | |
| 8/8/2014 | Q214 | ($0.05) | ($0.08) | $0.10 million | $0.01 million | View | N/A | |
| 5/12/2014 | Q114 | ($0.05) | ($0.04) | $0.35 million | $0.0042 million | View | N/A | |
| 3/10/2014 | Q4 2013 | ($0.06) | ($0.04) | | | View | N/A | |
| 11/11/2013 | Q3 | ($0.04) | ($0.09) | | | View | N/A | |
| 8/9/2013 | Q213 | ($0.05) | ($0.09) | $0.0781 million | $0.0025 million | View | N/A | |
| 5/10/2013 | Q1 2013 | ($0.52) | ($0.52) | $0.10 million | $0.10 million | View | N/A | |
| 3/15/2013 | Q4 2012 | ($0.52) | ($0.39) | | | View | N/A | |
| 11/9/2012 | Q312 | ($0.04) | ($0.04) | | | View | N/A | |
| 8/10/2012 | Q2 2012 | ($0.78) | ($0.57) | | | View | N/A | |
| 5/9/2012 | Q1 2012 | | ($0.62) | | | View | N/A | |
| 3/29/2012 | Q4 2011 | ($0.78) | ($0.68) | | | View | N/A | |
| 11/9/2011 | Q3 2011 | ($0.91) | ($0.86) | | | View | N/A | |
| 8/10/2011 | Q2 2011 | | ($0.99) | | | View | N/A | |
| 5/10/2011 | Q1 2011 | ($1.30) | ($0.96) | | | View | N/A | |
| 3/16/2011 | Q4 2010 | ($1.30) | ($0.65) | | | View | N/A | |
| 11/16/2010 | Q3 2010 | ($1.43) | ($1.16) | | | View | N/A | |
| 8/16/2010 | Q2 2010 | | ($1.40) | | | View | N/A | |
| 5/17/2010 | Q1 2010 | | ($1.27) | | | View | N/A | |
| 3/31/2010 | Q4 2009 | | ($1.04) | | | View | N/A | |
| 11/17/2009 | Q3 2009 | | ($1.91) | | | View | N/A | |
| 8/13/2009 | Q2 2009 | | ($1.05) | | | View | N/A | |
| 5/15/2009 | Q1 2009 | | ($1.07) | | | View | N/A | |
| 3/31/2009 | Q4 2008 | | ($1.43) | | | View | N/A | |
| 11/13/2008 | Q3 2008 | | ($1.29) | | | View | N/A | |
| 8/14/2008 | Q2 2008 | | ($1.20) | | | View | N/A | |
| 5/15/2008 | Q1 2008 | | ($0.94) | | | View | N/A | |
| 3/28/2008 | Q4 2007 | | ($1.17) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Neuralstem (NASDAQ:CUR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Neuralstem (NASDAQ CUR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 15.43%
Institutional Ownership Percentage: 7.03%
Neuralstem (NASDAQ CUR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/17/2017 | Richard J Daly | CEO | Buy | 7,500 | $4.00 | $30,000.00 | 23,312 | |
| 3/24/2017 | Jones Jonathan Brian Lloyd | CFO | Buy | 5,455 | $5.50 | $30,002.50 | 7,859 | |
| 2/24/2017 | Richard J Daly | CEO | Buy | 2,591 | $3.86 | $10,001.26 | 15,812 | |
| 1/25/2017 | Richard J Daly | CEO | Buy | 2,841 | $3.52 | $10,000.32 | 13,221 | |
| 12/23/2016 | Richard J Daly | CEO | Buy | 32,259 | $0.31 | $10,000.29 | 134,939 | |
| 11/25/2016 | Richard J Daly | CEO | Buy | 35,715 | $0.28 | $10,000.20 | 102,680 | |
| 10/25/2016 | Richard J Daly | CEO | Buy | 35,715 | $0.28 | $10,000.20 | 66,965 | |
| 9/23/2016 | Richard J Daly | CEO | Buy | 31,250 | $0.32 | $10,000.00 | 31,250 | |
| 11/16/2015 | Karl Johe | Insider | Sell | 25,000 | $1.09 | $27,250.00 | 826,304 | |
| 11/9/2015 | Karl Johe | Insider | Sell | 25,000 | $1.18 | $29,500.00 | 851,304 | |
| 11/2/2015 | Karl Johe | Insider | Sell | 25,000 | $1.17 | $29,250.00 | 876,304 | |
| 10/26/2015 | Karl Johe | Insider | Sell | 25,000 | $1.13 | $28,250.00 | 901,304 | |
| 10/19/2015 | Karl Johe | Insider | Sell | 25,000 | $1.23 | $30,750.00 | 926,304 | |
| 10/12/2015 | Karl Johe | Insider | Sell | 25,000 | $1.31 | $32,750.00 | 951,304 | |
| 10/5/2015 | Karl Johe | Insider | Sell | 25,000 | $1.26 | $31,500.00 | 976,304 | |
| 9/28/2015 | Karl Johe | Insider | Sell | 25,000 | $1.64 | $41,000.00 | 1,001,304 | |
| 9/21/2015 | Karl Johe | Insider | Sell | 25,000 | $1.52 | $38,000.00 | 1,026,304 | |
| 9/2/2014 | Karl Johe | Insider | Sell | 6,000 | $4.09 | $24,540.00 | | |
| 8/1/2014 | Karl Johe | Insider | Sell | 6,000 | $2.78 | $16,680.00 | | |
| 7/1/2014 | Karl Johe | Insider | Sell | 6,000 | $4.17 | $25,020.00 | | |
| 6/2/2014 | Karl Johe | Insider | Sell | 6,000 | $4.25 | $25,500.00 | | |
| 5/5/2014 | William Clyde Oldaker | Director | Buy | 15,235 | $3.50 | $53,322.50 | | |
| 4/22/2014 | Richard Garr | CEO | Sell | 7,000 | $4.25 | $29,750.00 | | |
| 4/1/2014 | Karl Johe | Insider | Sell | 6,000 | $4.11 | $24,660.00 | | |
| 3/20/2014 | Karl Johe | Insider | Sell | 6,000 | $4.04 | $24,240.00 | | |
| 10/18/2013 | Karl Johe | Insider | Sell | 10,000 | $2.44 | $24,400.00 | | |
| 9/20/2013 | Karl Johe | Insider | Sell | 10,000 | $2.62 | $26,200.00 | | |
| 9/19/2013 | Karl Johe | Insider | Sell | 10,000 | $2.61 | $26,100.00 | | |
| 8/20/2013 | Karl Johe | Insider | Sell | 20,000 | $1.55 | $31,000.00 | | |
| 7/22/2013 | Karl Johe | Insider | Sell | 12,800 | $1.62 | $20,736.00 | | |
| 6/20/2013 | Karl Johe | Insider | Sell | 12,800 | $1.40 | $17,920.00 | | |
| 6/7/2013 | Richard Garr | CEO | Sell | 6,000 | $1.42 | $8,520.00 | | |
| 5/20/2013 | Karl Johe | Insider | Sell | 12,800 | $1.51 | $19,328.00 | | |
| 2/25/2013 | Richard Garr | CEO | Sell | 12,000 | $1.15 | $13,800.00 | | |
| 11/20/2012 | Karl Johe | Insider | Sell | 12,800 | $1.00 | $12,800.00 | | |
(Data available from 1/1/2013 forward)
Neuralstem (NASDAQ CUR) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Neuralstem (CUR) Presents At ARM's 6th Cell & Gene Therapy Investor Day - Slideshow
seekingalpha.com - April 20 at 8:33 AM |
 | International Stem Cell Corporation to Present Interim Clinical Results at the American Academy of Neurology
globenewswire.com - April 18 at 8:53 AM |
 | Blog Exposure - Idera Pharma Announces Clinical Development Support Agreement with Pillar Partners Foundation
finance.yahoo.com - April 18 at 8:53 AM |
 | Neuralstem (CUR) Downgraded by ValuEngine
www.americanbankingnews.com - April 16 at 12:18 AM |
 | Neuralstem to Present Clinical Update at the Alliance for Regenerative Medicine 6th Annual Cell & Gene Therapy ...
www.nasdaq.com - April 11 at 8:50 AM |
| Neuralstem up 22% premarket on advancement of NSI-566
seekingalpha.com - April 11 at 8:50 AM |
| Today’s Research Reports on Trending Tickers: Neuralstem and Immunomedics
finance.yahoo.com - April 11 at 8:50 AM |
| Neuralstem Announces First Surgery Completed in Cervical Cohort of Phase 1 Clinical Trial in Patients with Chronic ...
globenewswire.com - April 10 at 5:17 PM |
| Neuralstem Reports Year End 2017 Fiscal Results and Business Update
globenewswire.com - April 2 at 9:25 AM |
| AIT Therapeutics (AITB) vs. Neuralstem (CUR) Financial Contrast
www.americanbankingnews.com - March 18 at 1:23 PM |
| Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cord Injury
finance.yahoo.com - March 14 at 11:41 AM |
| Neuralstem (CUR) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 14 at 1:35 AM |
 | Neuralstem (CUR) Reports Publication of Study in Nature Medicine Showing Benefits of NSI-566 in Primate Model of ... - StreetInsider.com
www.streetinsider.com - March 13 at 5:32 PM |
| Neuralstem to Participate at Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - March 13 at 5:32 PM |
| Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cord Injury
finance.yahoo.com - March 13 at 10:04 AM |
| Neuralstem to Participate at Upcoming Investor Conferences
finance.yahoo.com - March 12 at 5:17 PM |
| Neuralstem (CUR) and Theravance Biopharma (TBPH) Head to Head Comparison
www.americanbankingnews.com - March 2 at 11:22 PM |
 | Biotech Stocks' Research Reports Released on OvaScience, Pacific ... - PR Newswire (press release)
www.prnewswire.com - February 14 at 3:31 PM |
| Neuralstem to Participate at The Young Jewish Professionals CEO ... - GlobeNewswire (press release)
globenewswire.com - February 8 at 3:27 PM |
 | Neuralstem to Participate at The Young Jewish Professionals CEO Healthcare Symposium
feeds.benzinga.com - February 8 at 7:45 AM |
| Neuralstem - Burning Cash, Looking For Answers - Seeking Alpha
seekingalpha.com - February 8 at 6:53 AM |
| Financial Review: Innocoll (INNL) versus Neuralstem (CUR)
www.americanbankingnews.com - January 30 at 3:18 PM |
| Neuralstem to Participate at Cell and Gene Therapy World - GlobeNewswire (press release)
globenewswire.com - January 22 at 8:25 AM |
| Neuralstem (CUR) Price Target Cut to $1.91 by Analysts at S&P Equity Research
www.americanbankingnews.com - January 11 at 4:08 PM |
| Neuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology - GlobeNewswire (press release)
globenewswire.com - January 7 at 10:44 PM |
| Neuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology
finance.yahoo.com - January 6 at 9:32 AM |
| Neuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology
feeds.benzinga.com - January 5 at 6:50 PM |
| Neuralstem, Inc. (CUR) Sees Significant Increase in Short Interest
www.americanbankingnews.com - December 31 at 4:22 AM |
| Financial Review: Neuralstem (CUR) vs. Emergent Biosolutions (EBS)
www.americanbankingnews.com - December 30 at 9:12 AM |
| ETFs with exposure to Neuralstem, Inc. : December 26, 2017
finance.yahoo.com - December 28 at 1:37 PM |
| Neuralstem (CUR) Appoints Xi Chen PhD to Board
www.streetinsider.com - December 20 at 9:32 AM |
| Today’s Research Reports on Trending Tickers: Geron Corporation and Neuralstem, Inc.
finance.yahoo.com - December 8 at 9:31 AM |
| ETFs with exposure to Neuralstem, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 5:44 PM |
 | Neuralstem Inc. (CUR) Surged To A 4-Month High On Study Results
www.rttnews.com - December 6 at 9:40 AM |
| 800%+ Revenue Growth Could Imply 200-300% Returns for This Small Cap Stock
finance.yahoo.com - December 6 at 9:40 AM |
| Neuralstem (CUR) Announces Positive Updated Data from Phase 2 Study of NSI-189 in Major Depressive Disorder
www.streetinsider.com - December 5 at 5:15 PM |
| Neuralstem, Inc. (CUR): Updated Phase II Trial Success in Major Depressive Disorder Takes the Street by Storm
finance.yahoo.com - December 5 at 5:15 PM |
| Does Neuralstem Inc’s (CUR) Past Performance Indicate A Stronger Future?
finance.yahoo.com - November 30 at 5:14 PM |
| Contrasting Neuralstem (CUR) and The Competition
www.americanbankingnews.com - November 18 at 11:14 AM |
| Neuralstem (CUR) Reports Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at at ACNP Meeting
www.streetinsider.com - November 17 at 1:37 PM |
| Neuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual Meeting
finance.yahoo.com - November 16 at 6:17 PM |
| Comparing Sophiris Bio (SPHS) & Neuralstem (CUR)
www.americanbankingnews.com - November 14 at 5:18 AM |
| Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update - GlobeNewswire (press release)
globenewswire.com - November 13 at 9:13 PM |
| Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update
finance.yahoo.com - November 13 at 12:41 PM |
| Neuralstem reports 3Q loss
finance.yahoo.com - November 13 at 12:41 PM |
| ETFs with exposure to Neuralstem, Inc. : November 10, 2017
finance.yahoo.com - November 10 at 5:35 PM |
| Neuralstem (CUR) Names Dr. David Recker as Chief Medical Officer - StreetInsider.com
www.streetinsider.com - November 10 at 7:26 AM |
| Neuralstem, Inc. :CUR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 10 at 7:26 AM |
| Neuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical Officer
finance.yahoo.com - November 9 at 12:11 AM |
| Neuralstem, Inc. (CUR) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - October 30 at 10:22 AM |
Neuralstem (NASDAQ:CUR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Neuralstem (NASDAQ:CUR) Income Statement, Balance Sheet and Cash Flow Statement
Neuralstem (NASDAQ CUR) Stock Chart for Thursday, April, 26, 2018
Loading chart…
